natgillin/translations-raw huggingface dataset:
Silapo 1 000 IU/0.3 ml solution for injection in pre-filled syringe Silapo 2 000 IU/0.6 ml solution for injection in pre-filled syringe Silapo 3 000 IU/0.9 ml solution for injection in pre-filled syringe Silapo 4 000 IU/0.4 ml solution for injection in pre-filled syringe Silapo 5 000 IU/0.5 ml solution for injection in pre-filled syringe Silapo 6 000 IU/0.6 ml solution for injection in pre-filled syringe Silapo 8 000 IU/0.8 ml solution for injection in pre-filled syringe
Silapo 1 000 i.e./0,3 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Silapo 2 000 i.e./0,6 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Silapo 3 000 i.e./0,9 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Silapo 4 000 i.e./0,4 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Silapo 5 000 i.e./0,5 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Silapo 6 000 i.e./0,6 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Silapo 8 000 i.e./0,8 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Silapo 10 000 i.e./1 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Silapo 20 000 i.e./0,5 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Silapo 30 000 i.e./0,75 ml raztopina za injiciranje v napolnjeni injekcijski brizgi Silapo 40 000 i.e./1 ml raztopina za injiciranje v napolnjeni injekcijski brizgi
Treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy).
o zdravljenje hude anemije ledvičnega izvora s spremljajočimi kliničnimi znaki, pri odraslih bolnikih z ledvično insuficienco, ki se jih še ne zdravi z dializo (glejte poglavje zdravljenje anemije in zmanjšanje potrebe po transfuzijah pri odraslih bolnikih, ki prejemajo kemoterapijo zaradi čvrstih tumorje, malignega limfoma ali multiplega mieloma, in za katere je transfuzija glede na splošno stanje bolnika tvegana (npr. kardiovaskularni status, anemičnost ob začetku kemoterapije).
Serious skin rashes including Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported in association with epoetin treatment.
V povezavi z zdravljenjem z epoetini so poročali o hudih kožnih izpuščajih, vključno s StevensJohnsonovim sindromom in toksično epidermalno nekrolizo.
Dose information
DRUGI PODATKI
Cases of antibody-mediated PRCA have been very rarely reported in chronic renal failure patients with erythropoietin administered by the subcutaneous route.
Pri bolnikih s kronično ledvično okvaro, ki se jih je zdravilo s subkutanimi injekcijami eritropoetina, so v zelo redkih primerih poročali o PRCA, do katere je prišlo zaradi protiteles.
- The active substance is epoetin zeta (produced by recombinant DNA technology in Chinese
- Učinkovina je epoetin zeta (pridobljen iz celične linije jajčnika kitajskega hrčka (CHO
Sodium hydroxide (pH adjuster) Hydrochloric acid (pH adjuster)
glicin levcin izolevcin treonin glutamatna kislina fenilalanin voda za injekcije natrijev hidroksid (za prilagoditev pH) klorovodikova kislina (za prilagoditev pH)
4 000 IU/0.4 ml
4 000 i.e./0,4 ml
Convulsion
Odmerjanje
A rise in haemoglobin of greater than 2 g/dl (1.25 mmol/l) over a four week period should be avoided.
V času štirih tednov se morate izogibati dvigu koncentracije hemoglobina, ki presega 2 g/dl (1,25 mmol/l).
1 pre-filled syringe contains 8 000 IU Epoetin zeta
1 napolnjena ijekcijska brizga vsebuje 8 000 i.e. epoetin zeta
Severe cutaneous adverse reactions (SCARs) including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), which can be life-threatening or fatal, have been reported in association with epoetin treatment.
V povezavi z zdravljenjem z epoetini so poročali o hudih kožnih neželenih učinkih (SCAR-severe cutaneous adverse reactions), vključno s Stevens-Johnsonovim sindromom (SJS) in toksično epidermalno nekrolizo (TEN), ki so lahko življenje ogrožajoči ali smrtni.
Common: may affect up to 1 in 10 people
Pogosti: pojavijo se lahko pri največ 1 od 10 bolnikov.
This regresses during the course of continued therapy.
Med nadaljevanjem zdravljenja se njihovo število zmanjša.
Solution for injection in pre-filled syringe.
raztopina za injiciranje v napolnjeni injekcijski brizgi bistra, brezbarvna raztopina
6 000 IU/0.6 ml
6 000 i.e./0,6 ml
• You may be given iron supplements before and during Silapo treatment to make it more effective.
• Med zdravljenjem z zdravilom Silapo in po njem boste morda prejemali tudi nadomestno železo za povečanje učinkovitosti zdravila.
Weight (kg)
450i.e./kg
Silapo 8 000 IU/0.8 ml solution for injection in pre-filled syringe Epoetin zeta
Silapo 8 000 i.e./0,8 ml raztopine za injiciranje v napolnjeni injekcijski brizgi epoetin zeta
A slower injection is preferable in patients who react to the treatment with “flu-like” symptoms.
Pri bolnikih, ki na postopek reagirajo s simptomi podobnimi gripi, se priporoča počasneje iniciranje.
1 pre-filled syringe contains 5 000 IU Epoetin zeta
1 napolnjena ijekcijska brizga vsebuje 5 000 i.e. epoetin zeta
Use in adult patients receiving haemodialysis Your doctor will maintain your haemoglobin concentration between 10 and 12 g/dl (6.2 - 7.5 mmol/l).
Vaš zdravnik bo vašo koncentracijo hemoglobina ohranjal na vrednosti med 10 in 12 g/dl (6,2-7,5 mmol/l).
Silapo 1 000 IU
Silapo 1 000 i.e.
Serum electrolytes (substances in your blood) should be monitored in chronic renal failure patients.
Pri bolnikih s kronično ledvično okvaro je treba meriti elektrolite v serumu (snovi v krvi).
Silapo 30 000 IU/0.75 ml solution for injection in pre-filled syringe Epoetin zeta
Silapo 30 000 i.e./0,75 ml raztopine za injiciranje v napolnjeni injekcijski brizgi epoetin zeta
As an increased incidence of thrombotic vascular events (TVEs) has been observed in cancer patients receiving erythropoietic agents (see section 4.8), this risk should be carefully weighed against the benefit to be derived from treatment (with Silapo) particularly in cancer patients with an increased risk of thrombotic vascular events, such as obesity and patients with a prior history of TVEs (e.g. deep venous thrombosis or pulmonary embolism).
Pri bolnikih z rakom, ki so prejemali zdravila z eritropoetinom (glejte poglavje 4.8), je bilo opaziti porast trombotičnih vaskularnih zapletov (TVE - thrombotic vascular event), tako da je treba pazljivo pretehtati koristi in tveganja terapije z zdravilom Silapo.
2 000 IU/0.6 ml
2 000 i.e./0,6 ml
Arthralgia, Bone pain, Myalgia, Pain in extremity
Bolezni mišično-skeletnega sistema in vezivnega tkiva artralgija, bolečina v kosteh, mialgija, bolečina v okončinah pogosti
Hypertension, Venous and arterial thromboses
Žilne bolezni zvišan krvni tlak, venske in arterijske tromboze pogosti hipertenzivna kriza neznana
1 pre-filled syringe contains 20 000 IU Epoetin zeta
1 napolnjena ijekcijska brizga vsebuje 20 000 i.e. epoetin zeta
1 pre-filled syringe of 0.75 ml solution for injection 4 pre-filled syringes of 0.75 ml solution for injection
1 napolnjena injekcijska brizga z 0,75 ml raztopine za injiciranje 4 napolnjenih injekcijskih brizg z 0,75 ml raztopine za injiciranje
Severe cutaneous adverse reactions
Hudi kožni neželeni učinki
Serum electrolytes should be monitored in chronic renal failure patients.
Pri bolnikih s kronično ledvično okvaro je treba meriti elektrolite v serumu.
There may be a moderate dose-dependent rise in the platelet count within the normal range during treatment with erythropoietin.
V času zdravljenja z eritropoetinom lahko pride znotraj normalnih mej do, od odmerka odvisnega, zvišanja trombocitov.
1 pre-filled syringe contains 6 000 IU Epoetin zeta
1 napolnjena ijekcijska brizga vsebuje 6 000 i.e. epoetin zeta
• Diarrhoea
• Bruhanje.
• Respiratory tract congestion, such as stuffy nose and sore throat, has been reported in patients with kidney disease not yet on dialysis.
• Pri bolnikih z boleznijo ledvic, ki niso na dializi, so poročali o kongestiji dihal, kot je zamašen nos ali bolečine v grlu.
Silapo 8 000 IU/0.8 ml solution for injection in pre-filled syringe 1 pre-filled syringe with 0.8 ml solution for injection contains 8 000 international units (IU) epoetin zeta* (recombinant human erythropoietin).
Silapo 8 000 i.e./0,8 ml raztopina za injiciranje v napolnjeni injekcijski brizgi 1 napolnjena injekcijska brizga z 0,8 ml raztopine za injiciranje vsebuje 8 000 mednarodnih enot (i.e.) epoetina zeta * (rekombinantnega humanega eritropoetina).
Chills, Influenza like illness, Injection site reaction, Oedema peripheral
Splošne težave in spremembe na mestu aplikacije pireksija zelo pogosti mrzlica, gripi podobna bolezen, reakcija na mestu injiciranja, periferni edem pogosti neučinkovitost zdravila neznana
Kidney patients
Ledvični bolniki
Silapo 8 000 IU/0.8 ml solution for injection in pre-filled syringe EU/1/07/432/013
Silapo 8 000 i.e./0,8 ml raztopina za injiciranje v napolnjeni injekcijski brizgi EU/1/07/432/013
Serious skin reactions including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported in association with epoetin treatment.
V povezavi z zdravljenjem z epoetini so poročali o hudih kožnih reakcijah, vključno s StevensJohnsonovim sindromom (SJS) in toksično epidermalno nekrolizo (TEN).
Silapo 8 000 IU/0.8 ml solution for injection in pre-filled syringe 0.8 ml solution for injection in pre-filled syringe Type I glass with a fixed steel injection needle and a plunger stopper with PTFE coating.
Silapo 8 000 i.e./0,8 ml raztopina za injiciranje v napolnjeni injekcijski brizgi 0,8 ml raztopine za injiciranje v napolnjeni brizga iz stekla tipa I s fiksno jekleno iglo in zamaškom s teflonsko prevleko.
Respiratory tract congestion, which includes events of upper respiratory tract congestion, nasal congestion and nasopharyngitis, have been reported in studies with extended interval dosing in adult patients with renal insufficiency not yet undergoing dialysis.
V študijah s podaljšanim odmernim intervalom pri odraslih bolnikih z zmanjšanim delovanjem ledvic, ki se še ne zdravijo z dializo, so poročali o kongestiji dihal z dogodki, pri katerih je prišlo do kongestije zgornjih dihalnih poti, nosne kongestije in nazofaringitisa.
Silapo 30 000 IU/0.75 ml solution for injection in pre-filled syringe 0.75 ml solution for injection in pre-filled syringe Type I glass with a fixed steel injection needle and a plunger stopper with PTFE coating.
Silapo 30 000 i.e./0,75 ml raztopina za injiciranje v napolnjeni injekcijski brizgi 0,75 ml raztopine za injiciranje v napolnjeni brizga iz stekla tipa I s fiksno jekleno iglo in zamaškom s teflonsko prevleko.
Excipient with known effect Each pre-filled syringe contains 0.38 mg phenylalanine.
Pomožne snovi z znanim učinkom Ena napolnjena injekcijska brizga vsebuje 0,38 mg fenilalanina.
Silapo 5 000 IU/0.5 ml solution for injection in pre-filled syringe Epoetin zeta
Silapo 5 000 i.e./0,5 ml raztopine za injiciranje v napolnjeni injekcijski brizgi epoetin zeta
An increased incidence of thrombotic vascular events (see section 4.4 and section 4.8 - General) has been observed in patients receiving erythropoietic agents.
Pri bolnikih, ki so prejemali zdravila z eritropoetinom, so opazili zvečano incidenco trombotičnih vaskularnih dogodkov (glejte poglavji 4.4 in 4.8 - Splošni).
SYRINGE LABELS
NALEPKA/BRIZGA
1 pre-filled syringe contains 40 000 IU Epoetin zeta
1 napolnjena ijekcijska brizga vsebuje 40 000 i.e. epoetin zeta
Haemoglobin variability should be addressed through dose management, with consideration for the haemoglobin target range of 10 g/dl (6.2 mmol/l) to 12 g/dl (7.5 mmol/l).
Zaradi variabilnosti koncentracij hemoglobina pri posameznikih je treba odmerek prilagoditi, pri tem pa upoštevati ciljni razpon hemoglobina od 10 g/dl (6,2 mmol/l) do 12 g/dl (7,5 mmol/l).
Always use this medicine exactly as your doctor has told you.
Pri uporabi tega zdravila natančno upoštevajte navodila svojega zdravnika.
Intravenous route
Intravensko dajanja
1 pre-filled syringe contains 10 000 IU Epoetin zeta
1 napolnjena ijekcijska brizga vsebuje 10 000 i.e. epoetin zeta
1 pre-filled syringe of 1 ml solution for injection 4 pre-filled syringes of 1 ml solution for injection
1 napolnjena injekcijska brizga z 1 ml raztopine za injiciranje 4 napolnjenih injekcijskih brizg z 1 ml raztopine za injiciranje
Silapo 30 000 IU/0.75 ml solution for injection in pre-filled syringe 1 pre-filled syringe with 0.75 ml solution for injection contains 30 000 international units (IU) epoetin zeta* (recombinant human erythropoietin).
Silapo 30 000 i.e./0,75 ml raztopina za injiciranje v napolnjeni injekcijski brizgi 1 napolnjena injekcijska brizga z 0,75 ml raztopine za injiciranje vsebuje 30 000 mednarodnih enot (i.e.) epoetina zeta * (rekombinantnega humanega eritropoetina).
Following subcutaneous injection, serum levels of erythropoietin are much lower than the levels achieved following intravenous injection, the levels increase slowly and reach a peak between 12 and 18 hours postdose.
Po subkutani injekciji so koncentracije eritropoetina v serumu veliko nižje kot pa je to primer pri intravenskih injekcijah.
Silapo should be administered subcutaneously.
Zdravilo Silapo je treba dajati subkutano.
A sustained haemoglobin level of greater than 12 g/dl should be avoided; guidance for appropriate dose adjustment for when haemoglobin values exceeding 12 g/dl (7.5 mmol/l) are observed are described below.
Navodila za primerno prilagajanje odmerka v primeru ugotovljenih vrednosti hemoglobina, ki presegajo 12 g/dl (7,5 mmol/l), so navedena spodaj.
C.
Fe.
1 pre-filled syringe contains 4 000 IU Epoetin zeta
1 napolnjena ijekcijska brizga vsebuje 4 000 i.e. epoetin zeta
Silapo 5 000 IU Injection Epoetin zeta iv/sc use
Silapo injekcija 5 000 i.e. epoetin zeta i.v.
Silapo 6 000 IU/0.6 ml solution for injection in pre-filled syringe EU/1/07/432/011
Silapo 6 000 i.e./0,6 ml raztopina za injiciranje v napolnjeni injekcijski brizgi EU/1/07/432/011
Silapo 40 000 IU/1 ml solution for injection in pre-filled syringe Epoetin zeta
Silapo 40 000 i.e./1 ml raztopine za injiciranje v napolnjeni injekcijski brizgi epoetin zeta
Silapo 4 000 IU/0.4 ml solution for injection in pre-filled syringe Epoetin zeta
Silapo 4 000 i.e./0,4 ml raztopine za injiciranje v napolnjeni injekcijski brizgi epoetin zeta
Silapo 5 000 IU/0.5 ml solution for injection in pre-filled syringe EU/1/07/432/009
Silapo 5 000 i.e./0,5 ml raztopina za injiciranje v napolnjeni injekcijski brizgi EU/1/07/432/009
Silapo 30 000 IU/0.75 ml solution for injection in pre-filled syringe EU/1/07/432/018
Silapo 30 000 i.e./0,75 ml raztopina za injiciranje v napolnjeni injekcijski brizgi EU/1/07/432/018
1 pre-filled syringe of 1 ml solution for injection 6 pre-filled syringes of 1 ml solution for injection
1 napolnjena injekcijska brizga z 1 ml raztopine za injiciranje 6 napolnjenih injekcijskih brizg z 1 ml raztopine za injiciranje
Silapo 20 000 IU/0.5 ml solution for injection in pre-filled syringe Epoetin zeta
Silapo 20 000 i.e./0,5 ml raztopine za injiciranje v napolnjeni injekcijski brizgi epoetin zeta
Silapo 5 000 IU/0.5 ml solution for injection in pre-filled syringe 1 pre-filled syringe with 0.5 ml solution for injection contains 5 000 international units (IU) epoetin zeta (recombinant human erythropoietin).
Silapo 5 000 i.e./0,5 ml raztopina za injiciranje v napolnjeni injekcijski brizgi 1 napolnjena injekcijska brizga z 0,5 ml raztopine za injiciranje vsebuje 5 000 mednarodnih enot (i.e.) epoetina zeta * (rekombinantnega humanega eritropoetina).
Silapo 3 000 IU/0.9 ml solution for injection in pre-filled syringe EU/1/07/432/005
Silapo 3 000 i.e./0,9 ml raztopina za injiciranje v napolnjeni injekcijski brizgi EU/1/07/432/005
The use of Silapo in patients scheduled for major elective orthopaedic surgery and not participating in an autologous blood predonation programme is contraindicated in patients with severe coronary, peripheral arterial, carotid or cerebral vascular disease, including patients with recent myocardial infarction or cerebral vascular accident.
Pri bolnikih, naročenih na večji elektivni ortopedski kirurški poseg in ki niso vključeni v program avtolognega zbiranja krvi, je uporaba zdravila Silapo kontraidicirana, če imajo hudo
Silapo 3 000 IU/0.9 ml solution for injection in pre-filled syringe Epoetin zeta
Silapo 3 000 i.e./0,9 ml raztopine za injiciranje v napolnjeni injekcijski brizgi epoetin zeta
What Silapo contains
Kaj vsebuje zdravilo Silapo
1 pre-filled syringe contains 30 000 IU Epoetin zeta
1 napolnjena ijekcijska brizga vsebuje 30 000 i.e. epoetin zeta
Silapo 4 000 IU/0.4 ml solution for injection in pre-filled syringe EU/1/07/432/007
Silapo 4 000 i.e./0,4 ml raztopina za injiciranje v napolnjeni injekcijski brizgi EU/1/07/432/007
Silapo 10 000 IU/1 ml solution for injection in pre-filled syringe Epoetin zeta
Silapo 10 000 i.e./1 ml raztopine za injiciranje v napolnjeni injekcijski brizgi epoetin zeta
Silapo 8 000 IU Injection Epoetin zeta iv/sc use
Silapo injekcija 8 000 i.e. epoetin zeta i.v.
Silapo 4 000 IU/0.4 ml solution for injection in pre-filled syringe 0.4 ml solution for injection in pre-filled syringe Type I glass with a fixed steel injection needle and a plunger stopper with PTFE coating.
Silapo 4 000 i.e./0,4 ml raztopina za injiciranje v napolnjeni injekcijski brizgi 0,4 ml raztopine za injiciranje v napolnjeni brizga iz stekla tipa I s fiksno jekleno iglo in zamaškom s teflonsko prevleko.
Silapo 5 000 IU/0.5 ml solution for injection in pre-filled syringe 0.5 ml solution for injection in pre-filled syringe Type I glass with a fixed steel injection needle and a plunger stopper with PTFE coating.
Silapo 5 000 i.e./0,5 ml raztopina za injiciranje v napolnjeni injekcijski brizgi 0,5 ml raztopine za injiciranje v napolnjeni brizga iz stekla tipa I s fiksno jekleno iglo in zamaškom s teflonsko prevleko.
1 pre-filled syringe of 0.5 ml solution for injection 4 pre-filled syringes of 0.5 ml solution for injection
1 napolnjena injekcijska brizga z 0,5 ml raztopine za injiciranje 4 napolnjenih injekcijskih brizg z 0,5 ml raztopine za injiciranje
The starting dose may be adjusted by your doctor depending on how your anaemia responds to treatment; you will usually receive Silapo until 1 month after the end of chemotherapy.
Začetni odmerek bo Vaš zdravnik po potrebi prilagajal, odvisno od tega, kako se Vaša anemija odziva na zdravljenje.
Silapo 6 000 IU/0.6 ml solution for injection in pre-filled syringe Epoetin zeta
Silapo 6 000 i.e./0,6 ml raztopine za injiciranje v napolnjeni injekcijski brizgi epoetin zeta
Silapo 20 000 IU/0.5 ml solution for injection in pre-filled syringe EU/1/07/432/017
Silapo 20 000 i.e./0,5 ml raztopina za injiciranje v napolnjeni injekcijski brizgi EU/1/07/432/017
Silapo 2 000 IU/0.6 ml solution for injection in pre-filled syringe Epoetin zeta
Silapo 2 000 i.e./0,6 ml raztopine za injiciranje v napolnjeni injekcijski brizgi epoetin zeta
1 pre-filled syringe of 0.8 ml solution for injection 6 pre-filled syringes of 0.8 ml solution for injection
1 napolnjena injekcijska brizga z 0,8 ml raztopine za injiciranje 6 napolnjenih injekcijskih brizg z 0,8 ml raztopine za injiciranje
Silapo 4 000 IU/0.4 ml solution for injection in pre-filled syringe 1 pre-filled syringe with 0.4 ml solution for injection contains 4 000 international units (IU) epoetin zeta (recombinant human erythropoietin).
Silapo 4 000 i.e./0,4 ml raztopina za injiciranje v napolnjeni injekcijski brizgi 1 napolnjena injekcijska brizga z 0,4 ml raztopine za injiciranje vsebuje 4 000 mednarodnih enot (i.e.) epoetina zeta * (rekombinantnega humanega eritropoetina).
1 pre-filled syringe contains 3 000 IU Epoetin zeta
1 napolnjena ijekcijska brizga vsebuje 3 000 i.e. epoetin zeta
Silapo 40 000 IU/1 ml solution for injection in pre-filled syringe EU/1/07/432/019
Silapo 40 000 i.e./1, ml raztopina za injiciranje v napolnjeni injekcijski brizgi EU/1/07/432/019
Excipient with known effect Each pre-filled syringe contains 0.20 mg phenylalanine.
Pomožne snovi z znanim učinkom Ena napolnjena injekcijska brizga vsebuje 0,20 mg fenilalanina.
Silapo 2 000 IU/0.6 ml solution for injection in pre-filled syringe EU/1/07/432/003
Silapo 2 000 i.e./0,6 ml raztopina za injiciranje v napolnjeni injekcijski brizgi EU/1/07/432/003
Silapo 20 000 IU/0.5 ml solution for injection in pre-filled syringe 0.5 ml solution for injection in pre-filled syringe Type I glass with a fixed steel injection needle and a plunger stopper with PTFE coating.
Silapo 20 000 i.e./0,5 ml raztopina za injiciranje v napolnjeni injekcijski brizgi 0,5 ml raztopine za injiciranje v napolnjeni brizga iz stekla tipa I s fiksno jekleno iglo in zamaškom s teflonsko prevleko.
Silapo 20 000 IU/0.5 ml solution for injection in pre-filled syringe 1 pre-filled syringe with 0.5 ml solution for injection contains 20 000 international units (IU) epoetin zeta (recombinant human erythropoietin).
Silapo 20 000 i.e./0,5 ml raztopina za injiciranje v napolnjeni injekcijski brizgi 1 napolnjena injekcijska brizga z 0,5 ml raztopine za injiciranje vsebuje 20 000 mednarodnih enot (i.e.) epoetina zeta * (rekombinantnega humanega eritropoetina).
1 pre-filled syringe of 0.9 ml solution for injection 6 pre-filled syringes of 0.9 ml solution for injection
1 napolnjena injekcijska brizga z 0,9 ml raztopine za injiciranje 6 napolnjenih injekcijskih brizg z 0,9 ml raztopine za injiciranje
Silapo 3 000 IU/0.9 ml solution for injection in pre-filled syringe 0.9 ml solution for injection in pre-filled syringe Type I glass with a fixed steel injection needle and a plunger stopper with PTFE coating.
Silapo 3 000 i.e./0,9 ml raztopina za injiciranje v napolnjeni injekcijski brizgi 0,9 ml raztopine za injiciranje v napolnjeni brizga iz stekla tipa I s fiksno jekleno iglo in zamaškom s teflonsko prevleko.
Silapo 10 000 IU/1 ml solution for injection in pre-filled syringe EU/1/07/432/015
Silapo 10 000 i.e./1 ml raztopina za injiciranje v napolnjeni injekcijski brizgi EU/1/07/432/015
• If there is a medical need to reduce the time before your operation, you will be given a daily dose of 300 IU/kg for up to ten days before surgery, on the day of surgery and for four days immediately afterwards.
• Če obstaja medicinska potreba za zmanjšanje časa pred operacijo, boste prejemali dnevni odmerek
1 pre-filled syringe contains 2 000 IU Epoetin zeta
1 napolnjena ijekcijska brizga vsebuje 2 000 i.e. epoetin zeta
Silapo 20 000 IU Injection Epoetin zeta iv/sc use
Silapo injekcija 20 000 i.e. epoetin zeta i.v.
PRCA has been very rarely reported mostly in patients with kidney disease after months to years of treatment with Silapo and other products that stimulate red blood cell production.
Po več mesecih do letih zdravljenja z zdravilom Silapo in drugimi zdravili za spodbujanje tvorbe rdečih krvnih celic so zelo redko poročali o PRCA, večinoma pri bolnikih z boleznijo ledvic.
Silapo 40 000 IU/1 ml solution for injection in pre-filled syringe 1 ml solution for injection in pre-filled syringe Type I glass with a fixed steel injection needle and a plunger stopper with PTFE coating.
Silapo 40 000 i.e./1, ml raztopina za injiciranje v napolnjeni injekcijski brizgi 1 ml raztopine za injiciranje v napolnjeni brizga iz stekla tipa I s fiksno jekleno iglo in zamaškom s teflonsko prevleko.
1 pre-filled syringe of 0.5 ml solution for injection 6 pre-filled syringes of 0.5 ml solution for injection
1 napolnjena injekcijska brizga z 0,5 ml raztopine za injiciranje 6 napolnjenih injekcijskih brizg z 0,5 ml raztopine za injiciranje
Excipient with known effect Each pre-filled syringe contains 0.25 mg phenylalanine.
Pomožne snovi z znanim učinkom Ena napolnjena injekcijska brizga vsebuje 0,25 mg fenilalanina.
Check with your doctor if you are not sure.
Če ste negotovi, se posvetujte s svojim zdravnikom.
Major elective orthopaedic surgery
Večji elektivni ortopedski kirurški poseg
3H-thymidine incorporation in the erythroid nucleated spleen cells has been found in vitro (mouse spleen cell culture) after incubation with erythropoietin.
In vitro (celična kultura mišje vranice) so ugotovili povečan obseg vgrajevanja